GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » Total Long-Term Liabilities

Aurobindo Pharma (BOM:524804) Total Long-Term Liabilities : ₹24,557 Mil (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Aurobindo Pharma Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Aurobindo Pharma's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ₹24,557 Mil.

Aurobindo Pharma Total Long-Term Liabilities Historical Data

The historical data trend for Aurobindo Pharma's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Total Long-Term Liabilities Chart

Aurobindo Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,599.50 11,916.90 15,443.60 30,215.80 24,557.00

Aurobindo Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30,215.80 - 28,689.10 - 24,557.00

Aurobindo Pharma Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Aurobindo Pharma Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (BOM:524804) » Definitions » Total Long-Term Liabilities
Comparable Companies
BOM:500488 NSE:ALKEM BOM:500257 BOM:532321 BOM:543064 BOM:532296 BOM:543904 BOM:524494 BOM:500124 BOM:532331 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
AUROPHARMA:India
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Website
https://www.aurobindo.com
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines